MetaCap

Alterity Therapeutics (ATHE) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alterity Therapeutics (ATHE) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 56.7% versus a loss of 71.6%. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%TELO-71.56%
+75%-2%-79%
Nov 21, 20251 yearNov 20, 2026
ATHE-24.00%TELO-92.72%
+244%+67%-109%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus TELO key metrics
MetricATHETELO
Share price$1.52$0.364
Market cap$29.02M$26.82M
1-day change-8.16%-17.24%
YTD return-50.65%-72.63%
1-year return-56.70%-71.56%
5-year return-85.38%—
EPS (TTM)$-0.90$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-10.41M
52-week high$5.89$1.58
52-week low$1.52$0.353
Distance from 52-week high-74.19%-76.96%
Analyst consensusnonenone
Avg. price target upside+771.71%+998.90%
Average volume89.63K126.14K
Shares outstanding19.09M73.68M
Employees11—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATHE has outperformed TELO by 14.9 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

ATHE vs TELO FAQ

Which is bigger, Alterity Therapeutics or Telomir Pharmaceuticals?

Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $26.82M for Telomir Pharmaceuticals (TELO).

Which stock has performed better over the past year, ATHE or TELO?

ATHE returned -56.70% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons